Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for stem cell transplant patients: combo therapy targets severe GVHD

NCT ID NCT07340723

First seen Jan 17, 2026 · Last updated Jun 16, 2026 · Updated 14 times

Summary

This study tests whether adding ruxolitinib to standard steroids works better than steroids alone for grade II acute graft-versus-host disease (GVHD), a common complication after stem cell transplant. About 168 adults who have had a first stem cell transplant for blood cancer and develop GVHD within 100 days will take part. The main goal is to see if the combination improves response at day 28.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEM CELL TRANSPLANT COMPLICATIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100853, China

Conditions

The condition(s) this trial relates to.

acute graft versus host disease disease related to hematopoietic stem cell transplant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.